Neurofibromatosis type 1 associated with pheochromocytoma: a case report with a brief review of the literature

We presented the clinical case of neurofibromatosis type 1 (NF-1) associated with pheochromocytoma (PHEO) in a man under 40 years old without family history. The diagnosis of NF-1 was established based on 4 signs of the disease (multiple café au lait macules, scoliotic changes in posture, the presence of multiple neurofibromas, Lisch nodules). The diagnosis of PHEO was determined by a significant increase of free metanephrin/normethanephrin levels in daily urine, a malignant CT phenotype of the right adrenal tumor, and confirmed by pathomorphological study. Genetic tests revealed a new mutation in one of the alleles of NF1 gene, a deletion of a 566 bp gene fragment, including exon 19 with a size of 73 bp. This mutation leads to splicing of exons 18 and 20, frameshift, and termination of protein synthesis. A study of the level of transcription of the genes associated with PHEO (RET, TMEM127, MAX, FGFR, MET, MERTK, BRAF, NGFR, Pi3, AKT, MTOR, KRAS, MAPK) was conducted, a statistically significant decrease in the level of transcription of the KRAS and BRAF genes and increase in the level of transcription of the TMEM127 gene in comparison with control samples have been detected. This case demonstrates the need for timely recognition of NF-1 for further appropriate patient’s follow up and show the effectiveness of a multidisciplinary approach to the diagnosis and treatment of NF-1-associated catecholamine-secreting tumors.

1. Farschtschi S, Mautner VF, Cecilia A, et al. The Neurofibromatoses. Dtsch Arztebl. 2020; 117:354-360. doi: https://doi.org/10.3238/arztebl.2020.0354

2. Evans DG, Howard E, Giblin C, et al. Birth incidence and prevalence of tumor-prone syndromes: Estimates from a UK family genetic register service. Am J Med Genet A. 2010;152(2):327-332. doi: https://doi.org/10.1002/ajmg.a.33139

3. Evans DG, Bowers NL, Tobi S, et al. Schwannomatosis: a genetic and epidemiological study. J Neurol Neurosurg Psychiatry. 2018;89(11):1215-1219. doi: https://doi.org/10.1136/jnnp-2018-318538

4. Evans DGR. Neurofibromatosis type 2. In: Handbook of Clinical Neurology. Vol 132. Elsevier B.V.; 2015:87-96. doi: https://doi.org/10.1016/B978-0-444-62702-5.00005-6

5. Boyd KP, Korf BR, Theos A. Neurofibromatosis type 1. J Am Acad Dermatol. 2009;61(1):1-14. doi: https://doi.org/10.1016/j.jaad.2008.12.051

6. Johnson KJ, Hussain I, Williams K, et al. Development of an international internet-based neurofibromatosis Type 1 Patient registry. Contemp Clin Trials. 2013;34(2):305-311. doi: https://doi.org/10.1016/j.cct.2012.12.002

7. Rasmussen SA, Yang Q, Friedman JM. Mortality in Neurofibromatosis 1: An Analysis Using U.S. Death Certificates. Am J Hum Genet. 2001;68(5):1110-1118. doi: https://doi.org/10.1086/320121

8. Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 2014;13(8):834-843. doi: https://doi.org/10.1016/S1474-4422(14)70063-8

9. Legius E, Messiaen L, Wolkenstein P, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genetics in Medicine. 2021;23(8):1506-1513. doi: https://doi.org/10.1038/s41436-021-01170-5

10. Gutmann DH, Ferner RE, Listernick RH, et al. Neurofibromatosis type 1. Nat Rev Dis Primers. 2017;3. doi: https://doi.org/10.1038/nrdp.2017.4

11. Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis. J Med Genet. 2007;44(2):81-88. doi: https://doi.org/10.1136/jmg.2006.045906

12. Landry JP, Schertz KL, Chiang YJ, et al. Comparison of Cancer Prevalence in Patients with Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population from 1985 to 2020. JAMA Netw Open. 2021;4(3). doi: https://doi.org/10.1001/jamanetworkopen.2021.0945

13. Zöller ME, Rembeck B, Odén A, Samuelsson M, Angervall L. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer. 1997;79(11):2125-2131. doi: https://doi.org/10.1002/(sici)1097-0142(19970601)79:11<2125:aid-cncr9>3.0.co;2-n

14. Menon RK, Ferrau F, Kurzawinski TR, et al. Adrenal cancer in neurofibromatosis type 1: case report and DNA analysis. Endocrinol Diabetes Metab Case Rep. 2015;2014. doi: https://doi.org/10.1530/edm-14-0074

15. Patil S, Chamberlain RS. Neoplasms Associated with Germline and Somatic NF1 Gene Mutations. Oncologist. 2012;17(1):101-116. doi: https://doi.org/10.1634/theoncologist.2010-0181

16. Kiuru M, Busam KJ. The NF1 gene in tumor syndromes and melanoma. Laboratory Investigation. 2017;97(2):146-157. doi: https://doi.org/10.1038/labinvest.2016.142

17. Képénékian L, Mognetti T, Lifante JC, et al. Interest of systematic screening of Pheochromocytoma in patients with neurofibromatosis type 1. Eur J Endocrinol. 2016;175(4):335-344. doi: https://doi.org/10.1530/EJE-16-0233

18. Zinnamosca L, Petramala L, Cotesta D, et al. Neurofibromatosis type 1 (NF1) and pheochromocytoma: Prevalence, clinical and cardiovascular aspects. Arch Dermatol Res. 2011;303(5):317-325. doi: https://doi.org/10.1007/s00403-010-1090-z

19. Walther M, Herring J, Enquist E, et al. VON Recklinghausen’s Disease and Pheochromocytomas.; 1999

20. Gruber LM, Erickson D, Babovic-Vuksanovic D, et al. Pheochromocytoma and paraganglioma in patients with neurofibromatosis type 1. Clin Endocrinol (Oxf). 2017;86(1):141-149. doi: https://doi.org/10.1111/cen.13163

21. Pappachan JM, Raskauskiene D, Sriraman R, et al. Diagnosis and management of pheochromocytoma: A practical guide to clinicians. Curr Hypertens Rep. 2014;16(7). doi: https://doi.org/10.1007/s11906-014-0442-z

22. Opocher G, Conton P, Schiavi F, et al. Pheochromocytoma in von Hippel-Lindau disease and neurofibromatosis type 1. Fam Cancer. 2005;4(1):13-16. doi: https://doi.org/10.1007/s10689-004-6128-y

23. Ebbehoj A, Stochholm K, Jacobsen SF, et al. Incidence and Clinical Presentation of Pheochromocytoma and Sympathetic Paraganglioma: A Population-based Study. Journal of Clinical Endocrinology and Metabolism. 2021;106(5):E2251-E2261. doi: https://doi.org/10.1210/clinem/dgaa965

24. Shinall MC, Solórzano CC. Pheochromocytoma in neurofibromatosis type 1: When should it be suspected? Endocrine Practice. 2014;20(8):792-796. doi: https://doi.org/10.4158/EP13417.OR

25. Eniseeva ES, Protasov K V, Vlasyuk TP, et al. Pheochromocytoma associated with neurofibromatosis type 1: A clinical case. Russian Journal of Cardiology. 2019;24(9):61-63. doi: https://doi.org/10.15829/1560–4071-2019-9-61-63

26. Yukina MYu, Avsievich ES, Pushkareva AS, et al. Atypical and typical course of neurofibromatosis type 1 in combination with pheochromocytoma. Endocrine Surgery. 2022;15(3):30-40. doi: https://doi.org/10.14341/serg12730

27. Petrik GG, Kosmacheva ED, Butaeva S V, t al. AS. Bilateral pheochromocytoma and a tumor of the jejunum with neurofibromatosis of type 1. Innovative Medicine of Kuban. 2019;(4):55-61. doi: https://doi.org/10.35401/2500-0268-2019-16-4-55-61

28. Ryabchenko EV, Dremlyuga NV, Mezhinskaya EM, Polyansky EA. Pheochromocytoma associated with primary hyperparathyroidism and type 1 neurofibromatosis. Khirurgiya Zhurnal im NI Pirogova. 2023;(7):120. doi: https://doi.org/10.17116/hirurgia2023071120

29. National Institutes of Health Consensus Development Conference. Neurofibromatosis Conference Statement National Institutes of Health Consensus Development Conference. 1988. http://archneur.jamanetwork.com/

30. Sabet FA, Majdzadeh R, Mostafazadeh Davani B, et al. Likelihood ratio of computed tomography characteristics for diagnosis of malignancy in adrenal incidentaloma: Systematic review and meta-analysis. J Diabetes Metab Disord. 2016;15(1). doi: https://doi.org/10.1186/s40200-016-0224-z

31. Terzolo M, Stigliano A, Chiodini I, et al. AME position statement on adrenal incidentaloma. Eur J Endocrinol. 2011;164(6):851-870. doi: https://doi.org/10.1530/EJE-10-1147

32. Alfred King-yin Lam. Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours. Endocr Pathol. 2017;28(3):213-227. doi: https://doi.org/10.1007/s12022-017-9484-5

33. Nölting S, Bechmann N, Taieb D, et al. Personalized Management of Pheochromocytoma and Paraganglioma. Endocr Rev. 2022;43(2):199-239. doi: https://doi.org/10.1210/endrev/bnab019